









Markets
/
Stocks
/
nasdaq-fulc
/

Fulcrum Therapeutics Inc

FULC

7.540USD

+0.220+3.01%

Close 09/18, 16:00（ET）Quotes delayed by 15 min

407.85MMarket Cap

LossP/E TTM



Fulcrum Therapeutics Inc

7.540

+0.220+3.01%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated: 2025-09-18

Key Insights

The company's fundamentals are relatively weak. Its valuation is considered undervalued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite a weak stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

71 / 506

Overall Ranking

171 / 4721

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 7 analysts

Buy

Current Rating

11.071

Target Price

+51.25%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on improving the lives of patients with genetically defined rare diseases in areas of high unmet medical need. The Company’s clinical product candidate, losmapimod, is developed for the potential treatment of facioscapulohumeral muscular dystrophy (FSHD). Its other clinical product candidate is FTX-6058, which is developed for the treatment of certain hemoglobinopathies, including sickle cell disease (SCD). In addition to product candidate development, the Company has developed a drug discovery approach that it employs to systematically identify and validate cellular drug targets that can potentially modulate gene expression to treat known root causes of genetically defined rare diseases. The Company has developed pociredir, which is designed to elevate the level of fetal hemoglobin, or HbF, for the treatment of people with SCD.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 1161.43% year-on-year.

Growing

The company is in a growing phase, with the latest annual income totaling USD 80.00M.

Fairly Valued

The company’s latest PE is -6.41, at a medium 3-year percentile range.

Institutional Selling

The latest institutional holdings are 52.98M shares, decreasing 33.97% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 3.15M shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of -0.35.

Financial Health

Currency: USD Updated: 2025-09-18

The company's current financial score is 7.26, which is higher than the Biotechnology & Medical Research industry's average of 6.93. Its financial status is weak, and its operating efficiency is high. Its latest quarterly revenue reached 0.00, representing a year-over-year decrease of 100.00%, while its net profit experienced a year-over-year decrease of 131.22%.

Score

Industry at a Glance

Previous score

7.26

Change



Financials

2.27

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

7.51

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

9.28

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.22

Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated: 2025-09-18

The company’s current valuation score is 2.80, which is lower than the Biotechnology & Medical Research industry's average of 3.06. Its current P/E ratio is -6.23, which is -3.50% below the recent high of -6.01 and -14623.84% above the recent low of -916.75.

Score

Industry at a Glance

Previous score

2.80

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 71/506

No Data

Earnings Forecast

Currency: USD Updated: 2025-09-18

The company’s current earnings forecast score is 7.71, which is lower than the Biotechnology & Medical Research industry's average of 8.03. The average price target for Fulcrum Therapeutics Inc is 12.00, with a high of 15.00 and a low of 5.00.

Score

Industry at a Glance

Previous score

7.71

Change

Support & Resistance

No Data

Analyst Rating

Based on 7 analysts

Buy

Current Rating

11.071

Target Price

+51.25%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

554

Total

Median

Average

Company name

Ratings

Analysts

Fulcrum Therapeutics Inc

FULC

CRISPR Therapeutics AG

CRSP

Ionis Pharmaceuticals Inc

IONS

Intellia Therapeutics Inc

NTLA

Exact Sciences Corp

EXAS

IQVIA Holdings Inc

IQV

...

111

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-09-18

The company’s current price momentum score is 6.75, which is higher than the Biotechnology & Medical Research industry's average of 6.32. Sideways: Currently, the stock price is trading between the resistance level at 8.01 and the support level at 6.49, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.75

Change

0.2

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(1)

Buy(4)

Indicators

Value

Direction

MACD(12,26,9)

0.149

Buy

RSI(14)

61.521

Neutral

STOCH(KDJ)(9,3,3)

69.854

Buy

ATR(14)

0.424

High Vlolatility

CCI(14)

105.650

Buy

Williams %R

21.711

Buy

TRIX(12,20)

0.254

Sell

StochRSI(14)

100.000

Overbought

Moving Average

Sell(0)

Neutral(0)

Buy(6)

Indicators

Value

Direction

MA5

7.246

Buy

MA10

7.238

Buy

MA20

6.914

Buy

MA50

7.079

Buy

MA100

6.748

Buy

MA200

5.212

Buy

Institutional Confidence

Currency: USD Updated: 2025-09-18

The company’s current institutional recognition score is 10.00, which is higher than the Biotechnology & Medical Research industry's average of 5.96. The latest institutional shareholding proportion is 97.95%, representing a quarter-over-quarter increase of 0.15%. The largest institutional shareholder is The Vanguard, holding a total of 3.15M shares, representing 5.82% of shares outstanding, with 3.45% decrease in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

RA Capital Management, LP

10.23M

TCG Crossover Management, LLC

5.25M

Suvretta Capital Management, LLC

5.07M

+51.79%

Adage Capital Management, L.P.

3.00M

Nantahala Capital Management, LLC

4.82M

+0.90%

BlackRock Institutional Trust Company, N.A.

3.93M

-9.88%

The Vanguard Group, Inc.

Star Investors

3.22M

-0.90%

Dimensional Fund Advisors, L.P.

1.41M

-0.82%

State Street Global Advisors (US)

1.25M

+0.57%

Risk Assessment

Currency: USD Updated: 2025-09-18

The company’s current risk assessment score is 3.24, which is lower than the Biotechnology & Medical Research industry's average of 3.33. The company's beta value is 2.88. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.